Navigation Links
Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
Date:10/7/2009

THE WOODLANDS, Texas, Oct. 7/PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it is offering to sell, subject to market and other conditions, 27,500,000 shares of its common stock pursuant to an effective shelf registration statement, of which 16,412,613 shares are being offered through the underwriters and 11,087,387 shares are being offered to Invus, L.P., Lexicon's largest stockholder. Lexicon also intends to grant the underwriters a 30-day option to purchase up to an aggregate of 2,461,892 additional shares of common stock to cover over-allotments, if any. All of the shares in the offering are to be sold by Lexicon. Morgan Stanley will be acting as the sole book-runner for the offering, with Thomas Weisel Partners LLC acting as co-manager.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale is not permitted. The offering of these securities will be made only by means of a preliminary prospectus supplement and accompanying prospectus, copies of which may be obtained from Morgan Stanley & Co. Incorporated, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, telephone: (866) 718-1649, or by emailing prospectus@morganstanley.com.

The issuer has filed a registration statement (including a base prospectus) with the Securities and Exchange Commission, or SEC, for an offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and related prospectus supplements and other documents that the issuer has filed or will file with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, you may obtain a preliminary prospectus supplement and accompanying prospectus as indicated above.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by the company's research team.

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements related to Lexicon's expectations regarding the completion, timing and size of the proposed public offering. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "anticipated," "will," "proposed," and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Lexicon's results to differ materially from those indicated by these forward-looking statements, including risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the proposed public offering. There can be no assurance that Lexicon will be able to complete the proposed public offering on the anticipated terms, or at all. Additional risks and uncertainties relating to the proposed public offering, Lexicon and its business can be found under the headings "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission and under the heading "Risk Factors" in the preliminary prospectus supplement related to the proposed public offering to be filed with the Securities and Exchange Commission on October 7, 2009. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Lexicon Pharmaceuticals, Inc.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
2. Lexicon Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. Lexicon Appoints Judith Swain, M.D. to Board of Directors
4. Lexicon Pharmaceuticals to Present at ThinkEquity ThinkClinic
5. Lexicon Pharmaceuticals to Present at Bio InvestorForum
6. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
7. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
8. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
9. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
10. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
11. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... , Feb. 20, 2017  At the 2017 ... Orlando , IBM (NYSE: ... and clients. IBM Chairman, President and CEO ... keynote address today from 8:30-10 am ET, broadcast ... and ibm.com/industries/healthcare. Her remarks examine the advent of ...
(Date:2/18/2017)... IL (PRWEB) , ... February 17, 2017 , ... ... Blood and Marrow Transplantation (ASBMT) and the Center for International Blood & Marrow ... Convention Center in Orlando, Fla. , The combined scientific sessions offer ...
(Date:2/17/2017)... 17, 2017  BioGenex, a global leader in ... a novel system for quantitative immunohistochemistry (IHC). The ... of Rochester (NY, USA) and Konica-Minolta Inc. ( ... is able to accurately quantify the expression of ... growth factor receptor-2) in clinical samples. Quantitative IHC ...
(Date:2/16/2017)... ... 16, 2017 , ... EIT Digital has launched work to develop ... Pilot studies are about to get under way for the framework, which is designed ... The concept is expected to be transferred eventually to other industries that also require ...
Breaking Biology Technology:
(Date:2/8/2017)... , Feb. 8, 2017 About Voice ... voice to match it against a stored voiceprint ... as pitch, cadence, and tone are compared to ... minimal hardware installation, as most PCs already have ... different transactions. Voice recognition biometrics are most likely ...
(Date:2/7/2017)... Feb. 7, 2017   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... its innovative, highly flexible and award winning eClinical solution, ... iMedNet is a proven Software-as-a-Service (SaaS) clinical ... Capture (EDC), but also delivers an entire suite of ...
(Date:2/3/2017)... A new independent identity strategy consultancy firm ... . Designed to fill a critical niche in technical ... partners Mark Crego and Janice Kephart ... identity expertise that span federal governments, the 9/11 Commission, ... combined expertise has a common theme born from a ...
Breaking Biology News(10 mins):